Experimental work in animal models suggests that ventilation strategies using high frequency oscillatory ventilation or high frequency jet ventilation hold great promise in the prevention of lung injury in preterm infants. However, clinical trials of either modality demonstrate little clinical benefit and there are possibilities of adverse effects, including increased risk of intraventricular hemorrhage and poor neurological development.
The introduction of mechanical ventilation has led to improved survival in very low birth weight infants. 1 However, these improvements were shortly followed by the recognition that attempts at mechanical support led to significant lung injury. Northway et al. 2 were the first to report severe lung injury and inflammation, or 'bronchopulmonary dysplasia (BPD),' in infants supported with mechanical ventilation. Since that time, many improvements have been made in neonatal care, including the introduction of antenatal steroids and postnatal surfactant. However, BPD or chronic lung disease (CLD) remains a major problem in surviving premature neonates. Over 50% of extremely low birth weight infants have CLD, defined as oxygen dependency, at 36 weeks adjusted age. 3 In an attempt to prevent CLD, techniques of ventilation that theoretically decrease lung injury have been introduced. High frequency ventilation (HFV) is perhaps the most promising of these newer technologies. High frequency ventilators apply continuous distending pressure and deliver small tidal volumes (less than the anatomic dead space) superimposed on an extremely rapid rate. Three basic types of HFV are currently utilized: high frequency oscillatory ventilation (HFOV), high frequency flow interrupters (HFFI), and high frequency jet ventilation (HFJV). For purposes of this review, studies that used HFOV and HFFI are grouped together.
During the past decade, the use of HFV has doubled. 4 Over 20% of all very low birth weight infants receive HFV at some point during their hospital course. Despite the widespread introduction of HFV, there seems to be little appreciation of the clinical impact of this relatively new therapy. The following article will review the evidence from randomized, controlled trials synthesized in the systematic reviews of Bhuta, Henderson-Smart, and co-workers in the Cochrane Library. [5] [6] [7] [8] In particular, the review will focus on CLD and mortality, as well as potential side effects of therapy.
Elective HFOV vs conventional ventilation (cv)
Henderson-Smart et al. 5 reviewed the randomized, controlled trials comparing elective use of HFOV to CV in preterm infants who are mechanically ventilated for pulmonary dysfunction. When reading a systematic overview, it is important to review many of the same criteria that one would if one was reviewing a report of a randomized trial. One needs to know the hypothesis, the population under study, the entry criteria for subjects, the specific intervention and the control intervention, and the specific outcomes measured. For the review of elective HFOV, studies that enrolled preterm or low birth weight infants with pulmonary dysfunction mainly due to respiratory distress syndrome (RDS), who were thought to require intermittent positive pressure ventilation (IPPV), were considered eligible for inclusion. Studies were included if randomization to either elective HFOV or to CV occurred early in the course of RDS, soon after mechanical ventilation was commenced. In their search of the literature, the authors found 11 randomized, controlled trials that met the criteria.
9- 21 The size of the studies varied considerably, ranging from 43 infants 17 to 273 infants. 9 Although all studies included preterm infants, the upper limit for birth weight and gestational age differed between the studies. Most studies focused on the very low birth weight infant; however, three studies included infants as large as 2000 g. 9, 11, 12 The age and randomization varied from less than 1 h 16,20 to 9 h of age.
Piston Oscillator, the Infant Star Ventilator 16 and the French Piston Oscillator. 18 The studies of Johnson 20 and Van Reempts 21 used a variety of ventilators in the intervention group. In all trials, CV was administered using time-cycled, pressure-limited ventilators.
In an overall analysis, surprisingly few changes in clinical outcome were noted (Table 1) . No individual trial reported a decrease in pulmonary air leak. In fact, the meta-analysis of nine trials suggests a slight increase in the risk of pulmonary air leak (typical relative risk (RR) 1.14, 95% confidence interval (CI) 1.00, 1.29; typical risk difference (RD) 0.03, 95% CI 0.00, 0.07). Eight trials reported on neonatal mortality. None of the individual trials demonstrated any difference in mortality, and the overall analysis demonstrated no difference in the risk of death at 28 days (typical RR 1.08, 95% CI 0.86, 1.35; typical RD 0.01, 95% CI À0.02, 0.04). Five trials reported on oxygen dependency at 28 to 30 days in surviving infants. 12, [16] [17] [18] 21 Of these five trials, no individual trial reported a decrease in the risk of oxygen dependency at 28 to 30 days. The meta-analysis of these five trials demonstrated no difference in the risk of oxygen dependency at 28 days (typical RR 0.95, 95% CI 0.83, 1.09; typical RD À0.02, 95% CI À0.09, 0.04).
Status at 36 to 37 weeks postmenstrual age was not significantly altered by elective HFOV. No effect was demonstrated on death by 36 to 37 weeks postmenstrual age or at the time of discharge. Nine trials reported on mortality at this time point. None of the individual trials demonstrated a difference in mortality. The metaanalysis demonstrated no difference in mortality at 36 to 37 weeks postmenstrual age or discharge (typical RR 0.98, 95% CI 0.83, 1.16; typical RD 0.00, 95% CI À0.03, 0.03). Of the nine studies that reported on CLD at 36 to 37 weeks postmenstrual age or discharge in surviving infants, three demonstrated a decrease in risk. 11, 13, 19 The meta-analysis suggested a small decrease in the risk of CLD at 36 to 37 weeks postmenstrual age or discharge in a surviving infant (typical RR 0.88, 95% CI 0.79, 0.99; typical RD À0.04, 95% CI À0.08, 0.00).
The effect on the combined outcome death or CLD at 36 to 37 weeks postmenstrual age or discharge was marginally affected by elective HFOV. Nine trials reported on this outcome. The same three trials that reported an improvement in CLD at 36 to 37 weeks postmenstrual age or discharge also reported a decrease in death or CLD at that time point. 11, 13, 19 A marginal decrease in the risk of death or CLD at 36 to 37 weeks postmenstrual age or discharge was noted in the meta-analysis (typical RR 0.92, 95% CI 0.85, 1.00; typical RD À0.04, 95% CI À0.07, 0.00).
An increased risk of intraventricular hemorrhage (IVH) and white matter damage has been reported in individual trials of HFOV and HFJV. In the overview of all trials using elective HFOV, 10 trials reported on the incidence of IVH. Of these trials, no individual trial reported an increase in all grades of hemorrhage, although the HIFI trial 9 had a concerning trend in that direction. The metaanalysis did not suggest a significant increase in the risk of any IVH (typical RD 1.05, 95% CI 0.96, 1.15; typical RD 0.02, 95% CI À0.01, 0.05). Two trials of elective HFOV reported an increased risk of severe IVH.
9, 18 The meta-analysis did not demonstrate a significant increase in risk, although the trend was concerning (typical RR 1.11, 95% CI 0.95, 1.31; typical RD 0.02, 95% CI À0.01, 0.04). A trend towards increased white matter damage was shown in the HIFI trial; 9 however, a meta-analysis including 10 randomized, controlled trials did not suggest an increase in the risk (typical RR 1.10, 95% CI 0.84, 1.44; typical RD 0.01, 95% CI À0.01, 0.02).
Few trials have discussed long-term neurodevelopmental status. Only two trials reported on neurodevelopmental outcome at 1 to 3 years.
10, 14 The HIFI trial reported an increased risk of developmental abnormalities. 10 When combined with other small trials, an increased risk of neurodevelopmental problems was reported (typical RR 1.26, 95% CI 1.01, 1.58; typical RD 0.09, 95% CI 0.01, 0.17).
Henderson-Smart and co-workers performed a subgroups analysis of the trials that approached infants with a similar strategy regarding lung volume recruitment. This analysis omitted the HIFI trial, which was the trial with the most concerning results. 9 In this subgroup analysis, a decrease in the risk of death or BPD at 28 to 30 days was noted (typical RR 0.56, 95% CI 0.40, 0.77; typical RD À0.19, 95% CI À0.29, À0.09). However, no difference was noted regarding death at 36 to 37 weeks postmenstrual age or discharge, and a marginal decrease in CLD at 36 to 37 weeks postmenstrual age or discharge was reported in survivors (typical RR 0.88, 95% CI 0.79, 0.99; typical RD À0.05, 95% CI À0.09, 0.00). When only studies with volume recruitment were noted, the concern regarding the increased risk of IVH was no longer reported. Based on the results of the systematic overview, HendersonSmart and co-workers concluded that there was no clear evidence that elective HFOV, as compared with CV, offered important advantages when used as an initial ventilation strategy to preterm babies with acute pulmonary dysfunction. In particular, they noted that there was no evidence of a reduction in the death rate, although there may be a small reduction in the rate of CLD. This evidence that CLD was reduced is marginally significant and is weakened by the inconsistency of this effect across trials. Adverse effects on short-term neurological outcome were observed in some studies, but these effects were not significant overall. Information about the effects of long-term outcome was inadequate.
Rescue HFOV vs conventional ventilation for pulmonary dysfunction in preterm infants Bhuta et al. 6 conducted a systematic review of rescue HFOV vs CV for pulmonary dysfunction in preterm infants. The objectives of their review were to compare HFOV to CV in the treatment of preterm infants with severe lung disease. For purposes of the review, the authors defined severe lung disease as severe RDS on chest radiograph with or without interstitial air in an infant on IPPV with high inspired oxygen and high peak and mean airway pressures. As with the previous meta-analysis, randomized and quasirandomized controlled trials were included. Studies were included if they enrolled preterm infants requiring assisted ventilation with severe pulmonary dysfunction. In this review, only one trial was identified. 22 In this study, 182 preterm infants less than 35 weeks gestation, with birth weight more than 500 g and severe RDS (defined as requiring high peak and mean ventilator pressures, high inspired oxygen or having low arterial/alveolar oxygen ratios), who either had or were at risk of developing a pulmonary air leak, were entered. Infants could be randomized up to 48 h of age (mean age at entry 21 to 22 h). The primary outcome was development or worsening of pulmonary air leak. The HIFO study reported a decrease in the risk of any pulmonary air leak (RR 0.73, 95% CI 0.55, 0.96; RD À0.17, 95% CI À0.32, À0.03). There was no effect on the need for mechanical ventilation at 30 days (RR 0.94, 95% CI 0.54, 1.66). Neonatal mortality was similar in both groups (RR 1.11, 95% CI 0.61, 2.01; RD 0.02, 95% CI À0.10, 0.14). An increased risk of IVH was noted, (RR 1.77, 95% CI 1.06, 2.96; RD 0.16, 95% CI 0.02, 0.29). An increase in severe IVH was noted, but was not statistically significant (Table 2 ). There was insufficient information on the use of rescue HFOV to make recommendations regarding practice. The few data provided by the one randomized, controlled trial suggested that the harm may outweigh any benefit. For every six infants treated with rescue HFOV rather than CV, one case of pulmonary air leak of any type would be prevented and one case of IVH of any grade would be caused.
Elective HFJV vs conventional ventilation for RDS in preterm infants
Bhuta and Henderson-Smart 7 also reviewed the use of elective HFJV vs CV for RDS in preterm infants. The purpose of this review was to determine whether elective use of HFJV as compared to CV in preterm infants with RDS who were mechanically ventilated would decrease the incidence of CLD without causing serious adverse effects. Randomized and quasirandomized studies were considered. Studies that enrolled preterm infants born at less than 35 weeks gestational age or having a birth weight of less than 2000 g with pulmonary dysfunction principally due to RDS and who were receiving IPPV were considered eligible for evaluation. Included studies were those that randomized infants requiring mechanical ventilation early in the course of RDS to elective HFJV or CV. Infants receiving CV were stabilized on time-cycled, pressure limited ventilators with respiratory rates approximately 30 to 80 per minute. Three studies were included in the analysis. [23] [24] [25] In two trials, the intention was to use a lower mean airway pressure when switching from CV to HFJV, 23, 24 while in the third trial, 25 the intention was to use a higher mean airway pressure.
Two of the studies reported on air leak syndrome. Neither study individually demonstrated a difference in air leak syndrome, nor the meta-analysis of these two studies did not suggest a significant impact on air leak syndrome (typical RR 0.82, 95% CI 0.55, 1.22). Bronchopulmonary dysplasia (BPD) at 28 days was not affected by elective HFJV (typical RR 0.90, 95% CI 0.74, 1.09), nor was neonatal mortality (typical RR 0.86, 95% CI 0.49, 1.50). Keszler et al. 25 reported a decrease in CLD at 36 weeks in survivors. The meta-analysis that included this trial and one other trial that reported on this outcome demonstrated a trend towards decreased CLD at 36 weeks in survivors (typical RR 0.59, 95% CI 0.35, 0.99). Of concern, one of the trials of elective HFOV 24 had a trend towards increased severe IVH; however, when analyzed with the one other trial that reported on severe IVH, no significant increase was noted (typical RR 1.37, 95% CI 0.79, 2.37). In addition, Wiswell et al. 24 reported a significant increase in the risk of periventricular leukomalacia. When combined with the trial of Keszler et al., 25 no significant increase in risk was noted (typical RR 1.24, 95% CI 0.59, 2.61) ( Table 3 ). Trials that utilized a low volume strategy (as previously noted in the HFOV trials) reported the worst outcomes, particularly regarding adverse neurological effects.
In conclusion, Bhuta and Henderson-Smart noted that, although there may be benefits of elective HFJV regarding reduction in the risk of CLD at 28 days and 36 weeks postmenstrual age, there was a concerning increase in adverse neurological outcomes, particularly in the trial that utilized lower mean airway pressures.
Rescue HFJV vs CV for pulmonary dysfunction in preterm infants Only one trial reported on rescue HFJV compared with CV for the treatment of preterm infants with severe pulmonary dysfunction. The trial of Keszler et al. 26 included 144 newborn infants with pulmonary interstitial emphysema. Infants were randomly assigned to receive treatment with HFJV or rapid-rate conventional mechanical ventilation. If criteria for treatment failure were met, crossover to the alternate ventilator mode was permitted. Overall, 45 (61%) of 74 infants met treatment success criteria with HFJV compared with 26 (37%) of 70 treated with CV. Of the infants who failed initial therapy with CV, 45% of patients who crossed over to HFJV ultimately met success criteria. In contrast, only 9% of those who crossed over from HFJV to CV ultimately met success criteria. An analysis based on original treatment assignment demonstrated no significant differences in outcome. The risk of mortality (RR 1.07, 95% CI 0.67, 1.72), CLD (RR 0.77, 95% CI 0.54, 1.07), severe IVH (RR 0.74, 95% CI 0.42, 1.28), and new air leak (RR 0.76, 95% CI 0.46, 1.23) was similar in both groups. More necrotizing tracheobronchitis was seen in infants that received HFJV, but the number was small and the estimate of effect was imprecise (RR 1.33, 95% CI 0.29, 6.06). In a secondary analysis, when infants whose survival was a result of crossover treatment with the alternate therapy were excluded, the survival rate was 65% for HFJV, compared with 47% for CV (RR 0.66, 95% CI 0.67, 0.97) ( Table 4) .
Conclusion
Despite compelling data from animal experiments, the introduction of HFV has performed little to improve outcomes in very low birth weight infants. Although therapy may have a small impact on chronic lung injury, the possible increases in complications such as IVH remain of concern. 
